Showing 1201-1210 of 23044 results for "".
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
https://reachmd.com/programs/neurofrontiers/advancements-in-gmg-management-zilucoplan-as-an-alternative-to-c5-inhibitors/32858/Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome
https://reachmd.com/programs/cme/special-report-management-considerations-and-unmet-needs-in-lgs-and-dravet-syndrome/15112/Find out how you can manage polypharmacy in Lennox-Gastaut syndrome and Dravet syndrome and learn what new therapies are on the horizon.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivAesthetic Laser Innovators Discuss What Is Next
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/aesthetic-laser-innovators-discuss-what-is-next/56627/A roundtable discussion with Jill S. Waibel, MD, FACS, FAAD; R. Rox Anderson, MD, FAAD; Roy Geronemus, MD; and E. Victor Ross, MD, FAADUnresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence®
https://reachmd.com/programs/cme/unresectable-hcc-an-emerging-era-of-combination-therapy-a-clinical-convergence/12029/Don’t miss this opportunity to learn more about combination strategies, with practical guidance on their integration into clinical practice.Living with Psoriatic Arthritis: A Doctor-Patient Conversation
https://reachmd.com/programs/medical-industry-feature/psoriatic-arthritis-doctor-patient-conversation/32265/Meet Dawn, a patient who has been living with psoriatic arthritis for some time. After experiencing diffuse joint pain, crushing fatigue, and random rashes, she found that the treatment option BIMZELX® (bimekizumab-bkzx) made a big difference for her. Tune in to hear a conversation with Dr. ElizabetEye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
https://reachmd.com/cme/ophthalmology/eye-on-the-target-2421/33187/Specialists in eye care and oncology come together to discuss strategies to manage ocular toxicities associated with specific cancer drugs.Off-Label Medicines in Fighting COVID-19 & Through the Years
https://reachmd.com/programs/covid-19-frontlines/off-label-medicines-in-fighting-covid-19-through-the-years/11417/In hospitals across the country, doctors are using old malarial medicines to help battle COVID-19. But how did this even dawn on anyone to try it?The Psychosocial Dermal Axis
https://modernaesthetics.com/topics/skincare/the-psychosocial-dermal-axis/35421/It’s time for psychiatry, dermatology, and aesthetic medicine to unite and explore.Evidence-Based Guidelines for Managing Acne: Updates from AAD
https://reachmd.com/programs/clinicians-roundtable/evidence-based-guidelines-for-managing-acne-updates-from-aad/30057/The 2024 AAD guidelines provide updates and evidence-based recommendations for treating acne to improve patient outcomes. Here’s an overview.